What is B. Riley’s Estimate for VKTX Q4 Earnings?

Viking Therapeutics, Inc. (NASDAQ:VKTX) – Research analysts at B. Riley issued their Q4 2024 earnings per share estimates for shares of Viking Therapeutics in a research report issued on Thursday, November 21st. B. Riley analyst M. Mamtani expects that the biotechnology company will earn ($0.24) per share for the quarter. B. Riley has a “Strong-Buy” rating on the stock. The consensus estimate for Viking Therapeutics’ current full-year earnings is ($0.98) per share. B. Riley also issued estimates for Viking Therapeutics’ Q1 2025 earnings at ($0.29) EPS, Q2 2025 earnings at ($0.30) EPS, Q3 2025 earnings at ($0.32) EPS, Q4 2025 earnings at ($0.32) EPS, FY2025 earnings at ($1.23) EPS, FY2026 earnings at ($1.74) EPS, FY2027 earnings at ($2.53) EPS and FY2028 earnings at ($1.83) EPS.

Viking Therapeutics (NASDAQ:VKTX) last posted its quarterly earnings results on Wednesday, October 23rd. The biotechnology company reported ($0.22) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.24) by $0.02. During the same period in the prior year, the firm posted ($0.23) earnings per share.

Other equities analysts have also recently issued reports about the stock. William Blair reaffirmed an “outperform” rating on shares of Viking Therapeutics in a research note on Wednesday, November 20th. Oppenheimer reaffirmed an “outperform” rating and set a $138.00 price objective on shares of Viking Therapeutics in a research note on Wednesday, September 25th. HC Wainwright increased their target price on Viking Therapeutics from $90.00 to $102.00 and gave the company a “buy” rating in a research note on Monday, November 4th. StockNews.com upgraded Viking Therapeutics to a “sell” rating in a research report on Tuesday, October 15th. Finally, Morgan Stanley reiterated an “overweight” rating and issued a $105.00 price target on shares of Viking Therapeutics in a research report on Thursday, September 12th. One equities research analyst has rated the stock with a sell rating, ten have assigned a buy rating and two have given a strong buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $109.73.

Viking Therapeutics Trading Up 1.9 %

Shares of NASDAQ VKTX opened at $52.59 on Monday. Viking Therapeutics has a 1 year low of $11.55 and a 1 year high of $99.41. The firm’s 50-day moving average is $63.73 and its 200-day moving average is $60.25. The firm has a market capitalization of $5.86 billion, a PE ratio of -56.55 and a beta of 1.00.

Institutional Trading of Viking Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Oak Ridge Investments LLC bought a new position in Viking Therapeutics in the third quarter valued at approximately $837,000. Oppenheimer & Co. Inc. boosted its holdings in shares of Viking Therapeutics by 43.5% in the 3rd quarter. Oppenheimer & Co. Inc. now owns 102,324 shares of the biotechnology company’s stock valued at $6,478,000 after buying an additional 31,011 shares during the last quarter. Nvwm LLC bought a new position in shares of Viking Therapeutics in the third quarter valued at $999,000. Chartwell Investment Partners LLC grew its stake in shares of Viking Therapeutics by 88.0% in the third quarter. Chartwell Investment Partners LLC now owns 36,666 shares of the biotechnology company’s stock valued at $2,322,000 after buying an additional 17,159 shares in the last quarter. Finally, Aptus Capital Advisors LLC raised its position in Viking Therapeutics by 34.1% during the third quarter. Aptus Capital Advisors LLC now owns 38,143 shares of the biotechnology company’s stock worth $2,415,000 after acquiring an additional 9,699 shares in the last quarter. Institutional investors and hedge funds own 76.03% of the company’s stock.

Insider Activity

In other news, CEO Brian Lian sold 216,130 shares of Viking Therapeutics stock in a transaction that occurred on Friday, September 20th. The shares were sold at an average price of $70.83, for a total value of $15,308,487.90. Following the sale, the chief executive officer now directly owns 2,304,927 shares in the company, valued at $163,257,979.41. This trade represents a 8.57 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Lawson Macartney sold 2,000 shares of the stock in a transaction on Friday, November 8th. The stock was sold at an average price of $68.67, for a total transaction of $137,340.00. Following the transaction, the director now owns 47,965 shares of the company’s stock, valued at $3,293,756.55. The trade was a 4.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 371,117 shares of company stock worth $27,140,009 over the last three months. Corporate insiders own 4.70% of the company’s stock.

About Viking Therapeutics

Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.